EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP)
Clinical trials for EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP) explained in plain language.
Never miss a new study
Get alerted when new EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP) trials appear
Sign up with your email to follow new studies for EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a single drug preserve sight in rare retinal diseases? new study aims to find out.
Disease control OngoingThis study tests whether injecting adalimumab (an anti-inflammatory drug) directly into the eye can help preserve vision in people with retinitis pigmentosa or a related condition called EMAP. Thirty adults will receive three injections over four months, and researchers will meas…
Matched conditions: EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP)
Phase: PHASE1, PHASE2 • Sponsor: Centro de Pesquisa Rubens Siqueira • Aim: Disease control
Last updated May 26, 2026 07:56 UTC
-
Can your own blood help save your sight? new study tests PRP for rare eye diseases
Disease control OngoingThis early-stage study tests if injections of a patient's own platelet-rich plasma (PRP) can help preserve vision in people with retinitis pigmentosa or a related retinal disease called EMAP. Thirty adults will receive three injections over four months, and researchers will measu…
Matched conditions: EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP)
Phase: PHASE1, PHASE2 • Sponsor: Rubens Camargo Siqueira • Aim: Disease control
Last updated May 26, 2026 07:27 UTC